Articles

DCAT: Value Chain Insights — Tracking Expansions in High-Potency Manufacturing

In 2018, Societal^™ CDMO added a 24,000-square-foot facility, which included space for processing highly potent compounds, near its existing 97,000-square-foot contract pharmaceutical development and manufacturing facility. The expansion provides capabilities including formulation and analytical development, clinical trial packaging, and commercial manufacturing for highly potent compounds.